Literature DB >> 27031973

Risk estimates of cardiovascular diseases in a Sri Lankan community.

U K Ranawaka1, C N Wijekoon, A Pathmeswaran, A Kasturiratne, D Gunasekera, S Chackrewarthy, N Kato, A R Wickramasinghe.   

Abstract

OBJECTIVES: Quantifying the risk of cardiovascular disease (CVD) in a community is important in planning preventive strategies, but such data are limited from developing countries, especially South Asia. We aimed to estimate the risks of coronary heart disease (CHD), total CVD, and CVD mortality in a Sri Lankan community.
METHODS: A community survey was conducted in an urban health administrative area among individuals aged 35-64 years, selected by stratified random sampling. Their 10-year CHD, total CVD, and CVD mortality risks were estimated using three risk prediction tools: National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATP III), Systematic Coronary Risk Evaluation (SCORE), and World Health Organisation/ International Society of Hypertension (WHO/ISH) charts.
RESULTS: Among study participants (n=2985), 54.5% were females, and mean age (SD) was 52.4 (7.8) years. According to NCEP-ATP III ('hard' CHD risk), WHO/ISH (total CVD risk), and SCORE (CVD mortality risk) criteria, 25.4% (95% CI 23.6-27.2), 8.2% (95% CI 7.3-9.2), and 11.8 (95% CI 10.5-13.1) respectively were classified as at 'high risk'. The proportion of high risk participants increased with age. 'High risk' was commoner among males (30.3% vs 20.6%, p<0.001) according to NCEPATP III criteria, but among females (9.7% vs. 6.7%, p<0.001) according to WHO/ISH criteria. No significant gender difference was noted in SCORE risk categories.
CONCLUSIONS: A large proportion of individuals in this community are at risk of developing cardiovascular diseases, especially in older age groups. Risk estimates varied with the different prediction tools, and were comparatively higher with NCEP-ATP III charts.

Entities:  

Mesh:

Year:  2016        PMID: 27031973     DOI: 10.4038/cmj.v61i1.8253

Source DB:  PubMed          Journal:  Ceylon Med J        ISSN: 0009-0875


  5 in total

1.  A study of association between platelet volume indices and ST elevation myocardial infarction.

Authors:  Bhawani Yasassri Alvitigala; Mohammedu Aroos Fathima Azra; Darshana Udakara Kottahachchi; Madduma Mudiyanselage Priyamali Thusharika Jayasekera; Rajapaksha Arachchige Namal Kumarasiri Wijesinghe
Journal:  Int J Cardiol Heart Vasc       Date:  2018-09-11

2.  Assessment of cardiovascular risk in a slum population in Kenya: use of World Health Organisation/International Society of Hypertension (WHO/ISH) risk prediction charts - secondary analyses of a household survey.

Authors:  Amoolya Vusirikala; Frederick Wekesah; Catherine Kyobutungi; Oyinlola Oyebode
Journal:  BMJ Open       Date:  2019-09-04       Impact factor: 2.692

3.  Patients' experiences on accessing health care services for management of hypertension in rural Bangladesh, Pakistan and Sri Lanka: A qualitative study.

Authors:  Helena Legido-Quigley; Aliya Naheed; H Asita de Silva; Imtiaz Jehan; Victoria Haldane; Benjamin Cobb; Saeideh Tavajoh; Nantu Chakma; Anuradhani Kasturiratne; Sahar Siddiqui; Tazeen H Jafar
Journal:  PLoS One       Date:  2019-01-25       Impact factor: 3.240

4.  Estimation of total cardiovascular risk using the 2019 WHO CVD prediction charts and comparison of population-level costs based on alternative drug therapy guidelines: a population-based study of adults in Bangladesh.

Authors:  Jessica Yasmine Islam; M Mostafa Zaman; Mohammad Moniruzzaman; Shawkat Ara Shakoor; A H M Enayet Hossain
Journal:  BMJ Open       Date:  2020-07-19       Impact factor: 2.692

5.  mHealth nutrition and lifestyle intervention (mHENAL) to reduce cardiovascular disease risk in a middle-aged, overweight and obese population in Sri Lanka: Study protocol for a randomized controlled trial.

Authors:  Upul Senarath; Prasad Katulanda; Dulitha N Fernando; Nishan S Kalupahana; Kunarathinam Partheepan; Ranil Jayawardena; Gaya Katulanda; Michael J Dibley
Journal:  Contemp Clin Trials Commun       Date:  2019-09-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.